MariTide and retatrutide are two of the most closely watched investigational obesity drugs, and they illustrate just how differently companies are approaching the same basic set of hormone receptors. Neither is FDA-approved; both remain in clinical development. Here's how they compare on mechanism, trial results so far, and timeline.
Mechanism: Opposite Approaches to GIP
Retatrutide, developed by Eli Lilly, is a triple agonist: it activates the GLP-1, GIP, and glucagon receptors simultaneously, adding a third mechanism on top of the GLP-1/GIP dual-agonist approach used by tirzepatide. MariTide, developed by Amgen, takes a structurally different and mechanistically opposite approach to GIP: it's an antibody-peptide conjugate that blocks, or antagonizes, the GIP receptor while activating the GLP-1 receptor. The fact that both GIP activation (in retatrutide and tirzepatide) and GIP blockade (in MariTide) have each shown weight-loss benefit in trials is one of the more interesting open questions in current obesity drug research, and it reflects real scientific uncertainty about exactly how GIP signaling contributes to weight regulation, rather than a settled mechanism that one company got right and the other got wrong.
Dosing Frequency
This is the most immediately practical difference for patients. Retatrutide, like tirzepatide and semaglutide, is designed for weekly injection. MariTide's antibody-based design is built specifically to extend the drug's half-life enough to allow once-monthly dosing, a four-fold reduction in injection frequency if it's eventually approved at that dosing interval. Monthly dosing would be a meaningful convenience and adherence advantage, assuming MariTide's efficacy and safety profile hold up through Phase 3 and ultimately support that dosing schedule.
Efficacy Data So Far
The two drugs are at different stages of development, which makes direct comparison imperfect. Retatrutide is further along: its Phase 3 TRIUMPH program has reported weight loss results up to roughly 30% in some trial populations, among the highest reported for any obesity drug candidate to date. MariTide's data comes from an earlier stage, a Phase 2 trial in 592 adults, which reported 12% to 16% placebo-subtracted weight loss at 52 weeks in participants without diabetes, and a somewhat lower 8% to 12% range in participants with both obesity and type 2 diabetes. Phase 2 results, generated in a few hundred people, don't reliably predict exactly what a Phase 3 trial in thousands of participants will show, so this gap shouldn't be read as a settled verdict on which drug is more effective; MariTide's own Phase 3 MARITIME program, which began in 2024 and 2025, is what will determine whether its earlier results hold up at scale.
Safety Profile
Both drugs show a side-effect profile dominated by the gastrointestinal symptoms — nausea, vomiting, diarrhea, and constipation — common across this entire drug class. Neither has reported safety signals in available data that set it apart dramatically from other GLP-1-class drugs, though retatrutide's larger, more advanced trial program has naturally generated more safety data to evaluate so far simply because more participants have been studied for longer.
Regulatory Timeline
Neither drug is FDA-approved. Eli Lilly has publicly stated it is delaying retatrutide's FDA application to 2027, citing manufacturing data rather than efficacy or safety concerns. Amgen has not committed to a specific filing date for MariTide, and outside analysts have generally viewed an approval before 2028 as an optimistic estimate given the current stage of its Phase 3 program. Both timelines could shift based on how their respective Phase 3 results read out.
The Bottom Line
Retatrutide and MariTide represent two different bets on how to improve on the current generation of weekly GLP-1/GIP drugs — one by adding a third hormone target to a weekly injection, the other by re-engineering the GIP interaction entirely and extending dosing to once a month. Both are investigational, available only through clinical trial enrollment, and not a basis for treatment decisions today. Anyone interested in how these compare to currently available options should talk with their physician about what's actually FDA-approved now, rather than planning around results from drugs still in development.